December 2003

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, and manufacturing digitally.

June 25th 2024

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Susan Haigney

June 30th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

May 28th 2024

Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Close up the media plate on hand medical technicians working on bacterial culture and drug resistance of pathogens in laboratory. | Image Credit: © analysis121980 - stock.adobe.com

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.

3D Rendering of CAR - Chimeric Antigen Receptor Between T-Cell and Cancer Cell | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Siemens Finalizes $5.1B Dotmatics Acquisition

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

Related Content

Christopher Cole

July 1st 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, and manufacturing digitally.

June 25th 2024

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Susan Haigney

June 30th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

May 28th 2024

Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.